Antidepressants Market, By Product (Selective Serotonin Reuptake Inhibitor (SSRI), Serotonin-norepinephrine Reuptake Inhibitor (SNRI), Tricyclic Antidepressant (TCA), Monoamine Oxidase Inhibitor (MAOI), and Other Products), By Depressive Disorder (Major Depressive Disorder, Obsessive-compulsive Disorder (OCD), Generalized Anxiety Disorder (GAD), Panic Disorder (PD), and Other Depressive Disorders), and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Trends, Analysis, and Forecast till 2029

Antidepressants are drugs utilized in the treatment of depressive disorders such as dysthymia, anxiety, obsessive-compulsive disorder, eating disorders, chronic pain, and neuropathic pain. Depression is a medical illness that is associated with the brain. Symptoms of depression include lacking energy, feeling sad and tired, and having trouble in enjoying routine daily activities. As per data published by CDC, depression affects around 1 in every 5 individuals in the U.S. According to WHO (World Health Organization), at present around 350 million people are affected by depression across the world. Depression affects about 10% to 25% of women and 10% to 15% men. The antidepressant market accounted for US$ 13.2 billion in 2019 and is estimated to be US$ 26.1 billion by 2029 and is anticipated to register a CAGR of 7.1%.

Impact of COVID-19 on the market

The antidepressant market has triggered during the COVID-19 outbreak. The growing number of cases and fatalities is distressing mental health by elevating anxiety across the world. People who are already experiencing mental health problems are facing increased stress levels over the Covid-19 outbreak. This has surged the demand for antidepressant drugs.

Rising cases of depression

Depression mostly occurs due to the factors, such as stressful work environment and social isolation which has to lead the most toward the growing number of people suffering from depression. The number of people falling victim to depression and related disorders is projected to continue to rise, as a result of stressful work schedule due to technology, indecorous eating habits, increasing isolation from family and loved ones, and the lack of ability to adapt to the fast pace, at which, the world is moving forward. In countries, such as the United States and the United Kingdom, which are categorized by their rapid-paced economies, the percentage of the 'affected population' is quite high in every age group. As per the Office for National Statistics 2017, 1 in every 4 people in the United Kingdom are victim depression. Thus, the growing cases of depression are projected to propel the overall growth of the market studied across the world during the forecast period.

Side-effects and patent expiry

The antidepressants are Celexa (citalopram) and Lexapro (escitalopram), both of which are used to treat depression. Lexapro also helps to treat anxiety. Celexa and Lexapro can cause side effects mutual to others which include sleeplessness, nausea, dry mouth, sweating, and drowsiness. Celexa and Lexapro can also have serious side effects including excessive bleeding, vision issues, and seizures. In 2018, the tags of the medications contained a black warning box due to growth in suicide risk. Thus, the side-effects and patent expiry of antidepressants drugs are projected to hamper the growth of the antidepressants market.

The Antidepressants market is segmented based on the product, depressive disorder, and region.

On the basis of the product, the Antidepressants market is segmented into selective serotonin reuptake inhibitor (SSRI), serotonin-norepinephrine reuptake inhibitor (SNRI), a tricyclic Antidepressants (TCA), monoamine oxidase inhibitor (MAOI), and other products. Based on the depressive disorder, the target market is segmented into major depressive disorder, obsessive-compulsive disorder (OCD), and generalized anxiety disorder (GAD), panic disorder (PD), and other depressive disorders.

Regional Insights:

In the region, the antidepressants market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The North America Antidepressants market is the most leading market, owing to the presence of a large patient population suffering from various types of depression and anxiety disorders. Nevertheless, in the U.S. the Antidepressants market is currently saturated, as various Antidepressants drugs are available on prescription in the market. Furthermore, market maturity, loss of patent exclusivity, shortened drug lifecycles, and generic infiltration are the factors that contribute to the decline of the market growth in the region. The Asia Pacific is anticipated to register considerable growth due to several factors such as the high occurrence of psychiatric disorders and rapid economic growth in countries such as China, Japan, and Australia. Moreover, optimistic marketing approval for innovative medicines is likely to boost the target market over the forecast period.

Segments Covered in the Report:

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2019 to 2029.  For the purpose of this study, has segmented the Antidepressants market report based on product, depressive disorder, and region.

Antidepressants Market, By Product:

• Selective Serotonin Reuptake Inhibitor (SSRI)
• Serotonin-norepinephrine Reuptake Inhibitor (SNRI)
• Tricyclic Antidepressants (TCA)
• Monoamine Oxidase Inhibitor (MAOI)
• Other Products

Antidepressants Market, By Depressive Disorder:

• Major Depressive Disorder
• Obsessive-compulsive Disorder (OCD)
• Generalized Anxiety Disorder (GAD)
• Panic Disorder (PD)
• Other Depressive Disorders

 Antidepressants Market, By Region:

• North America
  • Middle East & Africa
    • • GCC
      • Israel
      • South Africa
      • Rest of Middle East & Africa
  • Latin America
    • • Brazil
      • Mexico
      • Rest of Latin America
  • Asia Pacific
    • • China
      • India
      • Japan
      • South Korea
      • Rest of Asia Pacific
  • Europe
    • • Germany
      • UK
      • France
      • Russia
      • Italy
      • Rest of Europe
  • • U.S.
    • Canada

The key players operating in the antidepressants market include Allergan Plc, Alkermes Plc, Bristol Myers Squibb Co., Eli Lilly and Co., Lundbeck A/S, GlaxoSmithKline Plc, Merck & Co., Inc., Pfizer Inc., Teva Pharmaceutical Industries Ltd., and Takeda Pharmaceutical Co. Ltd. Prominent players are focusing on expanding distribution networks as well as expanding geographical presence, as the Asia Pacific, the Middle East& Africa, and Latin America are developing regions with the improving economic conditions and the growing occurrence of various types of depressive disorders. For instance, in May 2018, Allergan, an Ireland based company, focused on developing, manufacturing, and commercializing branded pharmaceutical, biologic, device, surgical, and regenerative medicine products for patients around the world acquired Aptinyx for an unclosed amount. Aptinyx, a clinical-stage biopharmaceutical company focused on the discovery and development of transformative therapies for challenging neurologic disorders. Through this acquisition, Allergan gained important insights into NMDA receptor modulation as a potential therapeutic approach for depression.

• Allergan Plc
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Overview
  • Business Strategies

• Alkermes Plc
• Bristol Myers Squibb Co.
• Eli Lilly and Co.
• Lundbeck A/S
• GlaxoSmithKline Plc
• Merck & Co., Inc.
• Pfizer Inc.
• Teva Pharmaceutical Industries Ltd.
• Takeda Pharmaceutical Co. Ltd.

“*” marked represents similar segmentation in other categories in the respective section